Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Department of Neurology, Osaka General Medical Center, 3-1-56 Bandai-higashi, Sumiyoshi-ku, Osaka 558-8558, Japan.
J Neuroimmunol. 2022 Feb 15;363:577789. doi: 10.1016/j.jneuroim.2021.577789. Epub 2021 Dec 15.
The aim of this case report was to describe a potential anti-interleukin (IL)-6 treatment for cryptogenic new-onset refractory status epilepticus (C-NORSE).
Although an underlying immune-mediated pathogenesis is considered present in some C-NORSE cases, many cases do not respond to classical immunotherapies.
We describe the case of a 46-year-old woman with C-NORSE who achieved cessation of long-lasting status epilepticus following administration of tocilizumab, an IL-6 receptor-blocking antibody, although the final outcome was poor.
Anti-IL-6 treatment may prove effective in stopping status epilepticus in some C-NORSE cases.
本病例报告旨在描述一种潜在的抗白细胞介素（IL）-6 治疗方法，用于治疗隐源性新发耐药性癫痫持续状态（C-NORSE）。
尽管一些 C-NORSE 病例被认为存在潜在的免疫介导发病机制，但许多病例对经典免疫疗法没有反应。
我们描述了一例 46 岁女性 C-NORSE 病例，她在接受白细胞介素-6 受体阻断抗体托珠单抗治疗后，癫痫持续状态停止，尽管最终结果不佳。
抗 IL-6 治疗可能对某些 C-NORSE 病例的癫痫持续状态有效。
